Cartosense is a medical technology startup based in Bangalore, India, that makes AI-assisted surgical navigation systems for neurosurgeons and hospitals.

This Startup Deep Dive explains what Cartosense does, how it makes money, who backs it, how it compares with rivals and what could go wrong, using publicly available information. It is educational and not investment advice. Last updated: October 2026.

Cartosense in Brief

• What it is: Cartosense is an Indian Surgical navigation systems company based in Bangalore.
• Who it serves: patients, doctors, hospitals, diagnostic centres, insurers and employers.
• The company makes the C75 Surgical Navigation System, which has been reported as approved by CDSCO and installed at a hospital in Gujarat.
• The system uses AI and machine learning to map radiological images onto the patient's anatomy in real time.
• The company describes itself (company-stated) as the only company in India to have developed the complete surgical navigation stack, including optical tracking.
• Funding: reported: about $110,000 (listing may be unreliable).

Cartosense Quick Facts

Figures marked “reported” come from published reports and may differ between sources; “Not disclosed” means no reliable public figure was found.

What Is Cartosense?

Cartosense operates in the Surgical navigation systems space in India. Understanding a company like this starts with three questions: who is the customer, what painful problem is being solved, and why the solution is better than the alternatives. The sections below apply that lens to Cartosense.

• The company makes the C75 Surgical Navigation System, which has been reported as approved by CDSCO and installed at a hospital in Gujarat.
• The system uses AI and machine learning to map radiological images onto the patient's anatomy in real time.
• The company describes itself (company-stated) as the only company in India to have developed the complete surgical navigation stack, including optical tracking.

The Origin Story of Cartosense

Every company starts from a noticed gap and a team willing to commit to closing it. Strong origin stories are specific: a clear problem, a founding team with relevant skills, and an early product that real customers could test. Founder-market fit, meaning the team’s lived experience or technical depth in the domain, tends to predict how fast a young company learns.

• Founders: Nikhil Chandwadkar.
• Described as a Bangalore-based digital health startup supported by C-CAMP.
• Founded in 2017 (reported); co-founded by Nikhil Chandwadkar, with one database also listing Bhargava Chintalapati and Hem Rampal (reports differ).

Key Milestones and Challenges

No startup grows in a straight line. Early years usually involve slow adoption, product rewrites, hiring mistakes and funding gaps. In the Surgical navigation systems sector the common turning points are a first paying customer, a regulatory approval, a successful product demonstration or a funding round that lets the team invest ahead of demand. How a team responds to setbacks says more about resilience than any single headline.

• 2017: founded (reported).
• April 2024: C75 described as upcoming single-camera optical navigation system; accuracy tested against ASTM F2554 (company-stated).
• C75 later reported as CDSCO-approved and installed at Future Brain and Spine Hospital, Palanpur, Gujarat via distributor Toshbro Medicals.
• Grants from BIRAC, MeitY and C-CAMP (company-stated); October 2024 grant (reported).

Cartosense Funding and Investors

Funding history shows how much outside confidence a company has attracted and how long it can operate before needing more capital. Figures below are reported and may differ between sources; valuation figures are estimates unless the company has confirmed them.

• Grants from BIRAC, MeitY and C-CAMP (no amounts disclosed by company).
• Database listings give about $110,000 to $126,000 total across small rounds/grants, with C-CAMP and MedTech Innovator among investors (reported; treat with caution).

How Does Cartosense Make Money? (Business Model)

A business model describes who pays, how often and how much it costs to serve them. Strong models show repeat usage, improving margins with scale and acquisition channels that do not depend only on paid spend. Weak models show one-off sales, rising costs and growth that stops when spending stops. For companies selling to patients, doctors, hospitals, diagnostic centres, insurers and employers, sales cycles and contract size matter as much as headline growth.

• Sells surgical navigation hardware and software to hospitals, with distribution via partners such as Toshbro Medicals.
• Emphasis on cost-effective, long-lived capital equipment (8 to 10 year use horizon, company-stated).

The Numbers: Cartosense Financials

Financial figures show whether growth is turning into a self-sustaining business. Small and private companies often disclose little, so any number below is included only if it was found in public reporting.

• Audited revenue, profit and loss figures for Cartosense were not available in the public sources reviewed.
• Readers can check the company’s filings with the Registrar of Companies for the latest financial statements.

Market Opportunity for Cartosense

Market size is easy to exaggerate, so a useful approach separates the total market from the portion a company can realistically reach with its current product and distribution. The main forces behind demand in this sector are rising chronic disease, growing health insurance penetration, government programmes such as Ayushman Bharat and the Ayushman Bharat Digital Mission, and the shift of care to digital and home settings. Each of these widens the opportunity, but capital efficiency and execution decide who captures it.

• Company leadership has commented on rising demand for surgical navigation systems in India over the next five years (company-stated).

Technology and Product at Cartosense

Technology is rarely the whole moat, but it drives speed, cost and customer experience. A practical way to assess it is to separate the capability the company controls from the commodity infrastructure it rents. In this sector the important factors are clinical validity, data quality, integration with hospital and lab systems, and trust among doctors and patients.

• Wide-range single-camera optical tracking of instruments with infrared emitters (company-stated).
• AI/ML maps radiological images onto patient anatomy in real time; navigation software overlays CT/MR with tracked instruments.

Team and Culture at Cartosense

Teams are the most important and least measurable asset of a young company. Look at how complementary the founders’ skills are, how deep the second layer of leadership is, and how the company hires and retains specialists. Culture shows up in small repeated behaviours: how quickly bad news travels upward and whether commitments to customers are kept.

• Nikhil Chandwadkar, co-founder and CEO.
• Other listed co-founders: Bhargava Chintalapati and Hem Rampal (one database).

Cartosense Competitors: Competitive Landscape

A fair competitive analysis names direct rivals, adjacent players who could move into the space, and the customer’s default alternative. Durable advantages include proprietary data or technology, licences and approvals, brand trust, switching costs and cost leadership.

Risks and Challenges for Cartosense

• Only a small amount of disclosed funding is reported, which may limit scale against larger surgical navigation vendors.
• Regulatory risk: medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules.
• Clinical and liability risk: errors in care, diagnosis or product quality can damage trust quickly.
• Data privacy risk: health records are sensitive, and breaches or misuse can bring legal and reputational harm.
• Thin margins: low-ticket services and heavy customer-acquisition spend can keep unit economics weak.

Risk is not a reason to avoid a company; it is a reason to price it correctly and to monitor the right indicators over time. Regulation in this sector is shaped by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Cartosense Growth Outlook: What to Watch

• Company expects rising demand for surgical navigation in India over the next five years (company-stated).
• Key indicators: patient or user volumes, repeat usage, gross margin, clinical outcomes and cost of acquiring each customer.
• Funding position: Whether Cartosense can reach its next milestone before needing new capital.
• Regulation: Changes from the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act.

Industry Context: Where Cartosense Fits

India's healthcare market combines a large public system, a fast-growing private hospital sector and an increasingly digital layer. Government initiatives such as Ayushman Bharat and the Ayushman Bharat Digital Mission aim to widen insurance cover and create common digital health records, while telemedicine guidelines and the Digital Personal Data Protection Act shape how digital care and patient data can be used.

Demand is driven by chronic and lifestyle disease, an ageing population, rising insurance penetration and consumers who now expect to book, pay and consult online. Startups in this field compete on trust, clinical quality and convenience, and they must prove outcomes and safety as well as growth.

For readers new to this field, a useful habit is to separate announcements from evidence. A plan, a partnership or a funding headline describes intent, while a delivered product, a paying customer or an audited financial statement describes results. Comparing the two over time shows how reliably a company turns promises into outcomes.

Bull Case and Bear Case for Cartosense

An investment thesis is a short, testable statement of why a company could become far more valuable, together with what evidence would prove it wrong. The points below are general to this sector and are not forecasts for Cartosense.

Bull case

• Rising insurance cover and digital adoption expand the customer base.
• Strong clinical evidence builds trust with doctors and hospitals.
• Scale can improve unit economics in diagnostics and care delivery.

Bear case

• Regulatory changes can alter permitted products or business models.
• Customer acquisition costs can erode margins.
• A single safety or privacy incident can damage trust.

Lessons Founders and Investors Can Take from Cartosense

Studying a company in the Surgical navigation systems space offers lessons that go beyond any single firm. The points below are general lessons for the sector and are not claims about Cartosense.

• Trust is the real currency in healthcare, so quality control, clinical evidence and data protection must be built in from the start.
• Distribution through hospitals, clinics, insurers or employers can matter more than a standalone consumer app.
• Unit economics improve when repeat usage replaces expensive one-time customer acquisition.
• Regulatory approvals can take time, so timelines and cash planning should allow for them.
• Integration with existing hospital, lab and records systems reduces friction for adoption.

How to Evaluate Cartosense as a Startup

• Customer clarity: Can Cartosense name its customer and the problem it solves in one sentence?
• Evidence of demand: Look for repeat customers, signed contracts or measurable usage rather than announcements alone.
• Economics: Check whether margins improve as volume grows.
• Execution: Compare announced timelines with what has actually been delivered.
• Funding runway: Estimate how long current capital lasts at the present spending rate.
• Regulatory standing: Confirm required approvals are in place.
• Customer concentration: Check whether a few customers account for most of the revenue.
• Management depth: Look for experienced leaders beyond the founders and a stable core team.

The Takeaway

Cartosense is part of India’s growing Surgical navigation systems ecosystem. The useful lesson from studying it is the discipline of asking structured questions about customers, economics, advantage and resilience. Companies that answer them well, repeatedly and under pressure are the ones that endure. Readers should treat any single report, ranking or funding headline as one input among many, and should re-check key facts against recent company announcements. Because public information on young companies is often limited, patience in verifying claims is part of good analysis. This article is educational and is not investment advice.

• Clear customers and repeat demand matter more than announcements.
• Regulation and capital needs shape how fast a startup in this sector can grow.
• Track a few leading indicators over time rather than one headline metric.

Cartosense FAQs: Frequently Asked Questions

What is Cartosense?

Cartosense is a medical technology startup based in Bangalore, India, that makes AI-assisted surgical navigation systems for neurosurgeons and hospitals. It is profiled in the Startup Deep Dive series, which explains business model, funding, competitors and risks.

Who founded Cartosense?

Cartosense was founded by Nikhil Chandwadkar, and the company reports a founding year of 2017 (reported).

How much funding has Cartosense raised?

reported: about $110,000 (listing may be unreliable). Funding figures are reported and may differ between sources, so readers should check the latest company announcements.

How does Cartosense make money?

Cartosense earns revenue from its Surgical navigation systems products and services sold to patients, doctors, hospitals, diagnostic centres, insurers and employers. The exact revenue mix is described in the business model section and is not fully disclosed publicly.

Who are the competitors of Cartosense?

Reported rivals include Medtronic, Brainlab, Stryker, HRS Navigation. See the competitor comparison above for how they differ.

What are the main risks for Cartosense?

Main risks include medical devices, diagnostics, online pharmacy and telemedicine each face different and changing rules, funding and capital needs, competition and regulation by the CDSCO, state health regulators, the National Medical Commission and the Digital Personal Data Protection Act. This is educational content, not investment advice.

Related Startup Deep Dives: Scapia — Scapia raised $40M Series B led by Peak XV for travel cards | Kinara Capital — Kinara Capital: women-led MSME lender raised ~Rs 200 crore in 2022. Browse the full Startup Deep Dive series.

Source

Source: Publicly available data, published reports, industry research, and other credible sources.